journal article·2016-08-17

Polycaprolactone-based in situ implant containing curcumin-PLGA nanoparticles prepared using the multivariate technique

Narayanan Kasinathan, Muthukumar Amirthalingam, Neetinkumar D. Reddy, Meenashi B. Vanthi, Subrahmanyam M. Volety, Josyula Venkata Rao

Publisher page

Abstract

Studies on the effect of curcumin/PLGA ratio (CPR), stabilizer (PVA) concentration, homogenization speed, homogenization time, and sonication time on mean particle size (MPS) and percentage drug encapsulation (PDE) were performed using the multivariate technique. MPS and PDE were found to be more dependent on the interaction of sonication time with the other variables. Curcumin was released in a sustained manner from curcumin-PLGA nanoparticles (CPN). CPN improved the survival rate of Ehrlich ascites carcinoma (EAC)-bearing mice and controlled the EAC-induced change in hematological parameters. Histopathology of vital organs showed that the formulation was safe. Polycaprolactone was used in preparing an in situ implant containing CPN.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Curcumin's Biomedical Applications · Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India

References (28)

Show source-provided references
1. 10.1016/j.bcp.2009.09.00310.1016/j.bcp.2009.09.003 ↗
2. 10.1081/PDT-12001751710.1081/PDT-120017517 ↗
3. 10.3109/10837450.2011.64068810.3109/10837450.2011.640688 ↗
4. 10.3109/10837450.2012.69626910.3109/10837450.2012.696269 ↗
5. Ferreira AP · Pharm Dev Technol · 2014 · 1
6. 10.1016/j.aca.2007.07.01110.1016/j.aca.2007.07.011 ↗
7. 10.3109/0363904100369513910.3109/03639041003695139 ↗
8. 10.3109/10837450.2012.71023910.3109/10837450.2012.710239 ↗
9. 10.3109/10837450.2010.52258310.3109/10837450.2010.522583 ↗
10. Guideline ICHHT. 2009. Pharmaceutical development. Q8 (2R). As revised in August.
11. 10.3109/21691401.2015.101966810.3109/21691401.2015.1019668 ↗
12. Jelvehgari M · Iran Journal Pharm Res · 2011 · 10 · 457
13. Kasinathan N · Drug Deliv · 2014 · 23 · 1
14. Kasinathan N · Drug delivery · 2014 · 1
15. 10.1016/j.colsurfb.2012.06.02410.1016/j.colsurfb.2012.06.024 ↗
16. 10.1016/j.yexmp.2012.10.00710.1016/j.yexmp.2012.10.007 ↗
17. 10.1007/s11095-007-9511-110.1007/s11095-007-9511-1 ↗
18. Leleux J · Drug Dev Ind Pharm · 2013 · 1
19. 10.1208/s12248-008-9026-710.1208/s12248-008-9026-7 ↗
20. Narayanan K · J Drug Deliv · 2014 · 2014 · 948650
21. 10.1016/j.ejpb.2004.03.00310.1016/j.ejpb.2004.03.003 ↗
22. 10.1006/bbrc.2001.582310.1006/bbrc.2001.5823 ↗
23. 10.2174/18722111280265260610.2174/187221112802652606 ↗
24. Ranjan AP · Anticancer Research · 2013 · 33 · 3603
25. 10.1186/1477-3155-10-3810.1186/1477-3155-10-38 ↗
26. 10.1177/088532821142747310.1177/0885328211427473 ↗
27. Tabatabaei Mirakabad FS · Artif Cells Nanomed Biotechnol · 2014 · 17 · 1
28. 10.1016/j.drudis.2011.09.00910.1016/j.drudis.2011.09.009 ↗